Investor Presentaiton
Strong track record
Unique model
Large moat
Significant opportunity
Compounding growth
Expanding opportunity set driving accelerated capital deployment
5-year forward capital deployment target
Implied average annual cash deployed
>$7bn (1)
>50%
~$10-12bn (2)
(year-to-year variability expected)
$2.0-2.5bn (3)
~$1.5bn (1)
$4.0-5.0bn
Previous
New
May 17, 2022
Previous
New
May 17, 2022
Long-term potential
Increasing 5-year forward capital deployment target to $10-12bn
1. 2020 to 2025 outlook for capital deployment provided on February 17, 2021.
ROYALTY PHARMA
2. See slide 114 for factors that may impact our capital deployment target.
3. Royalty Pharma's 2020 to 2030 growth target assumes $2.0-2.5bn of capital deployed on average per year through 2030.
21View entire presentation